Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy We identified published studies from 1983 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback